Designates October of each year as "Opioid Abuse Prevention Month."
Impact
The joint resolution requires the Governor to issue an annual proclamation recognizing Opioid Abuse Prevention Month. It calls for public officials and citizens to engage in educational activities and programs in observance of this month. By formalizing this observance, AJR19 serves to enhance community awareness and response strategies concerning the opioid crisis, bringing attention to the necessary involvement of lawmakers, law enforcement, community leaders, and families in combating this epidemic. The resolution aims not only to inform the public on the dangers of opioid abuse but also to advocate for rehabilitation and support for those affected.
Summary
AJR19 is a joint resolution that designates October of each year as 'Opioid Abuse Prevention Month' in the state of New Jersey. The resolution aims to promote ongoing education about opioid abuse, recognize efforts aimed at combating this epidemic, and support those affected by opioid addiction. The resolution highlights the alarming statistics around opioid use in New Jersey and the growing challenges posed by the public health crisis. It draws on data from the Centers for Disease Control and Prevention, which asserts that opioid-related overdose death rates have tripled since 1990, with a significant portion attributed to prescription painkillers.
Contention
While AJR19 is largely a straightforward resolution aimed at increasing awareness and promoting educational activities regarding opioid abuse, the broader implications involve ongoing discussions around addiction treatment policies and resource allocation. Some may argue that while designating a month for awareness is beneficial, it must be complemented by effective legislative action and funding for treatment programs to truly address the crisis. Moreover, the bill's supporters emphasize the importance of engaging the community on this public health issue, while critics may question if the resolution will lead to substantial change without accompanying policy reforms in addiction services.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.